Business Practice

Angela Osborne has created her own space in the industry and is helping the cell and gene therapy industry bloom.

Nick Crabb explains the UK’s health technology assessment agency's (NICE's) approach to cell and gene therapies.

Regardless of how Britain leaves the European Union, the global pharma industry must always lobby for positive change.

Why the CVS-Aetna merger could be a transformative event for the pharmaceutical industry.

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

The Chinese pharmaceutical market is already more advanced than many in the West imagine – and it only looks set to go in one direction.

With the US back to divided government, the US pharma industry could be the number one target for politicians.

As ever, our industry will have to deal with its fair share of sociopolitical “fun” in 2019. But what can we do?

2019 Power List nominations close in just one month. Who’s in the running? Well, that’s up to you…

Mega mergers, state-of-the-art stem cell facility and humorous pharmaceutical ads… What’s new for pharma in business?